CD34 DNAM-1 CXCR4 Cell Population for Chronic Inflammation Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring chronic inflammation in diseases like HIV, hepatitis C, tuberculosis, and COPD lack specificity, as they cannot differentiate between disease progression and treatment effects, limiting personalized treatment evaluation.
Innovation Solution
Identification of a novel cell population characterized by CD34, DNAM-1 (CD226) bright, and CXCR4 expression, which correlates with chronic inflammation, allowing for its use as a diagnostic marker and therapeutic target, enabling the generation of mature NK cells and T cells for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If common inflammation markers (CRP, ESR, fibrinogen) are used for monitoring disease progression, then general inflammation status can be assessed, but fine differences in disease control and treatment effects cannot be identified
Solution Approach 1:
The invention segments the monitoring system by introducing a specific cell population marker (CD34+DNAM+CXCR4+) that divides the general inflammation assessment into distinct stages: early activation (CD34+DNAM+) and chronic persistence (CD34+DNAM+CXCR4+). This segmentation enables precise differentiation between disease progression and treatment response without requiring complex multi-marker panels.
2Reliability
If CD34+ cells are monitored in healthy subjects, then they are found localized to bone marrow, but they cannot be identified in peripheral blood or umbilical cord blood
Solution Approach 1:
The invention applies local quality by identifying that the CD34+DNAM+CXCR4+ cell population has distinct localization properties: in healthy subjects it is confined to bone marrow, while in chronic inflammation it relocates to peripheral blood. This localized expression pattern serves as a reliable marker for detecting pathological states without requiring complex detection methods, as the cells become accessible in peripheral blood during disease states.
3Adaptability or versatility
If existing inflammation markers are used, then general inflammatory status can be monitored, but personalized treatment evaluation cannot be performed
Solution Approach 1:
The invention implements feedback by using the CD34+DNAM+CXCR4+ cell population as a dynamic marker that responds to treatment effects. As treatment successfully controls chronic inflammation, the percentage of these cells decreases, providing real-time feedback on treatment efficacy. This enables personalized treatment evaluation by allowing clinicians to adjust therapy based on the evolving cell population dynamics specific to each patient's response.
Data Source
Figure 1a
Figure 1b
Figure 2
AI summary
The present invention relates to the identification of a new cell population of human lymphoid precursors characterized by the expression of markers such as CD34, DNAM- 1 (CD226) and CXCR4, the relative method for their identification and the relative uses in the therapeutic and diagnostic field.